Andrea Gombos

Dienst : Medische oncologie

accueil.oncologie [at] hubruxelles.be

Publicaties

Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.

Auteurs : Nuciforo P, Townend J, Piccart-Gebhart M, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, Di Cosimo S
Jaar : 2023
Journal : Eur J Cancer

How I treat endocrine-dependent metastatic breast cancer.

Auteurs : Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte JA, Ignatiadis M, Awada A
Jaar : 2023
Journal : ESMO Open

What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.

Auteurs : Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, Iorio MV
Jaar : 2022
Journal : Cancer Med

Author Correction: FDG positron emission tomography imaging and ctDNA detection as an early dynamic biomarker of everolimus efficacy in advanced luminal breast cancer.

Auteurs : Gombos A, Venet D, Ameye L, Vuylsteke P, Neven P, Richard V, Duhoux FP, Laes JF, Rothe F, Sotiriou C, Paesmans M, Awada A, Guiot T, Flamen P, Piccart-Gebhart M, Ignatiadis M, Gebhart G
Jaar : 2022
Journal : NPJ Breast Cancer

MONARCH-plus: the evidence of efficacy and safety of abemaciclib in countries with limited clinical research opportunitie

Auteurs : Awada A, Gombos A
Jaar : 2022
Journal : TBCR

Meer publicaties »

Andrea Gombos

Talen

Contact